Clinical Report: Early Outcomes of Thulium Fiber Laser Enucleation of Prostate

Overview

This study evaluates the early safety and feasibility of Thulium fiber laser enucleation of the prostate (ThuFLEP) in an Asian cohort. The findings indicate a high catheter-free rate and significant improvement in urinary symptoms without major complications.

Background

Benign prostatic hyperplasia (BPH) is a prevalent condition causing lower urinary tract symptoms (LUTS) in aging men. Traditional treatments like TURP have been the standard, but newer laser techniques, such as Thulium fiber laser enucleation, offer potential advantages in safety and efficacy. Understanding the outcomes of these newer techniques in diverse populations is crucial for optimizing BPH management.

Data Highlights

Key Findings

• No Clavien-Dindo grade ≥3 complications were observed.
• 87.5% of patients were catheter-free by day 1 post-surgery.
• 100% of patients were catheter-free by day 14 post-surgery.
• Significant reduction in PSA levels was noted at 3 months (p<0.001).
• At 12 months, no surgical or medical retreatment was required for the patients.

Clinical Implications

The findings support the use of ThuFLEP as a safe and effective option for managing BPH in Asian populations, particularly for patients with significant urinary retention. The high catheter-free rates and improvement in urinary symptoms suggest that this technique may enhance patient quality of life.

Conclusion

ThuFLEP using the SOLTIVE™ system shows promising early outcomes in safety and efficacy for BPH treatment in an Asian cohort. Further studies with larger sample sizes and longer follow-up are necessary to validate these findings.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. EAU Guidelines on the Management of Non-neurogenic Male LUTS - DISEASE MANAGEMENT
6. Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia
7. EAU Guidelines on the Management of Non-neurogenic Male LUTS - DISEASE MANAGEMENT
8. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K252787.pdf